Mark Goldberger

826 total citations
17 papers, 585 citations indexed

About

Mark Goldberger is a scholar working on Pharmacology, Infectious Diseases and Molecular Medicine. According to data from OpenAlex, Mark Goldberger has authored 17 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 6 papers in Infectious Diseases and 6 papers in Molecular Medicine. Recurrent topics in Mark Goldberger's work include Antibiotics Pharmacokinetics and Efficacy (7 papers), Antibiotic Resistance in Bacteria (6 papers) and Tuberculosis Research and Epidemiology (3 papers). Mark Goldberger is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (7 papers), Antibiotic Resistance in Bacteria (6 papers) and Tuberculosis Research and Epidemiology (3 papers). Mark Goldberger collaborates with scholars based in United States, United Kingdom and Canada. Mark Goldberger's co-authors include Jerrold J. Ellner, David M. Parenti, John Rex, Barry I. Eisenstein, John Tomayko, Aaron Dane, Thomas M. Shinnick, Samuel Dooley, William R. Jacobs and Margaret A. Fischl and has published in prestigious journals such as Journal of the American College of Cardiology, Clinical Infectious Diseases and Annals of the New York Academy of Sciences.

In The Last Decade

Mark Goldberger

17 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Goldberger United States 12 273 269 125 91 85 17 585
Thomas Haustein Switzerland 10 280 1.0× 190 0.7× 102 0.8× 135 1.5× 25 0.3× 16 680
Frank Tally United States 8 490 1.8× 188 0.7× 136 1.1× 66 0.7× 209 2.5× 10 805
Jürg Blaser Switzerland 14 107 0.4× 151 0.6× 129 1.0× 102 1.1× 223 2.6× 31 638
José Ramón Paño‐Pardo Spain 18 303 1.1× 435 1.6× 272 2.2× 34 0.4× 138 1.6× 55 1.1k
Raymond Cha United States 20 464 1.7× 242 0.9× 180 1.4× 58 0.6× 264 3.1× 41 1.1k
Adebola Ajao United States 11 204 0.7× 187 0.7× 109 0.9× 22 0.2× 30 0.4× 22 558
Vasiliki Rapti Greece 9 383 1.4× 109 0.4× 203 1.6× 29 0.3× 104 1.2× 29 771
Conrad J. Wilkowske United States 14 192 0.7× 309 1.1× 77 0.6× 83 0.9× 87 1.0× 33 569
Gunnar Jacobsson Sweden 19 564 2.1× 475 1.8× 67 0.5× 105 1.2× 39 0.5× 43 1.2k
Erasmus Kamugisha Tanzania 20 193 0.7× 263 1.0× 138 1.1× 39 0.4× 17 0.2× 48 1.1k

Countries citing papers authored by Mark Goldberger

Since Specialization
Citations

This map shows the geographic impact of Mark Goldberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Goldberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Goldberger more than expected).

Fields of papers citing papers by Mark Goldberger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Goldberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Goldberger. The network helps show where Mark Goldberger may publish in the future.

Co-authorship network of co-authors of Mark Goldberger

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Goldberger. A scholar is included among the top collaborators of Mark Goldberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Goldberger. Mark Goldberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Prins, Kurt W., et al.. (2021). Association of right ventricular dysfunction and pulmonary hypertension with adverse 30‐day outcomes in COVID‐19 patients. Pulmonary Circulation. 11(2). 1–9. 17 indexed citations
2.
Rex, John, George H. Talbot, Mark Goldberger, et al.. (2017). Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clinical Infectious Diseases. 65(1). 141–146. 47 indexed citations
3.
Goldberger, Mark. (2016). Beyond the GAIN Act: Some Thoughts on Expediting Antibacterial Development to Address the Problem of Antimicrobial Resistance. Pharmaceutical Medicine. 30(2). 71–78. 1 indexed citations
4.
Tomayko, John, John Rex, David M. Tenero, Mark Goldberger, & Barry I. Eisenstein. (2014). The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development. Clinical Pharmacology & Therapeutics. 96(2). 166–168. 13 indexed citations
5.
Rex, John, et al.. (2014). The evolution of the regulatory framework for antibacterial agents. Annals of the New York Academy of Sciences. 1323(1). 11–21. 23 indexed citations
6.
Rex, John, Barry I. Eisenstein, Jeff Alder, et al.. (2013). A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. The Lancet Infectious Diseases. 13(3). 269–275. 92 indexed citations
7.
Goldberger, Mark, et al.. (2010). ASCPT Task Force for Advancing Pharmacometrics and Integration into Drug Development. Clinical Pharmacology & Therapeutics. 88(2). 158–161. 7 indexed citations
8.
Goldberger, Mark, et al.. (2002). FDA’s role in responding to drug shortages. American Journal of Health-System Pharmacy. 59(15). 1423–1425. 25 indexed citations
9.
Powers, John H., David B. Ross, Erica Brittain, Renata Albrecht, & Mark Goldberger. (2002). The United States Food and Drug Administration and Noninferiority Margins in Clinical Trials of Antimicrobial Agents. Clinical Infectious Diseases. 34(6). 879–881. 17 indexed citations
10.
Yao, Siu‐Sun, Hugo Spindola‐Franco, Mark Menegus, et al.. (1997). Successful intracoronary thrombolysis in cocaine‐associated acute myocardial infarction. Catheterization and Cardiovascular Diagnosis. 42(3). 294–297. 2 indexed citations
11.
Ellner, Jerrold J., A. R. Hinman, Samuel Dooley, et al.. (1993). Tuberculosis Symposium: Emerging Problems and Promise. The Journal of Infectious Diseases. 168(3). 537–551. 93 indexed citations
12.
Ellner, Jerrold J., Mark Goldberger, & David M. Parenti. (1991). Mycobacterium avium Infection and AIDS: A Therapeutic Dilemma in Rapid Evolution. The Journal of Infectious Diseases. 163(6). 1326–1335. 190 indexed citations
13.
Goldberger, Mark. (1988). Antituberculosis Agents. Medical Clinics of North America. 72(3). 661–668. 11 indexed citations
14.
Ursell, Philip C., et al.. (1983). Kawasaki Syndrome in an Adult: Endomyocardial Histology and Ventricular Function During Acute and Recovery Phases of Illness. Journal of the American College of Cardiology. 2(2). 374–378. 26 indexed citations
15.
Parry, Michael F., Mark Goldberger, & Harold C. Neu. (1978). Therapy of serious infections with cefamandole. Infection. 6(5). 236–240. 2 indexed citations
16.
Neu, Harold C., et al.. (1978). Cefoxitin sodium and cephalothin in the treatment of serious infections. Journal of Antimicrobial Chemotherapy. 4(suppl B). 105–111. 5 indexed citations
17.
Appel, Gerald B., et al.. (1976). Pharmacokinetics of Cefamandole in the Presence of Renal Failure and in Patients Undergoing Hemodialysis. Antimicrobial Agents and Chemotherapy. 10(4). 623–625. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Haustein Breakdown of academic impact, for papers by Frank Tally Breakdown of academic impact, for papers by Jürg Blaser Breakdown of academic impact, for papers by José Ramón Paño‐Pardo Breakdown of academic impact, for papers by Raymond Cha Breakdown of academic impact, for papers by Adebola Ajao Breakdown of academic impact, for papers by Vasiliki Rapti Breakdown of academic impact, for papers by Conrad J. Wilkowske Breakdown of academic impact, for papers by Gunnar Jacobsson Breakdown of academic impact, for papers by Erasmus Kamugisha
Rankless by CCL
2026